madman
Super Moderator
Frontiers | Effects of oral fenugreek-derived preparations on testosterone-related outcomes in adult men: a systematic review and meta-analysis of randomized placebo-controlled trials
BackgroundFenugreek (Trigonella foenum-graecum)-derived preparations are widely marketed for male-health benefits related to testosterone, sexual function, b...
www.frontiersin.org
The current evidence does not support claims that fenugreek can reliably or clinically meaningfully increase testosterone (7–9). For users and clinicians, the most appropriate summary is that randomized trials suggest a small favorable direction for total testosterone, but the evidence is very uncertain and free testosterone does not show a stable benefit. Future trials should register protocols before recruitment; use standardized and chemically characterized fenugreek preparations; harmonize morning testosterone assay methods; measure SHBG and free testosterone using standardized protocols; transparently report sample-size handling and all prespecified outcomes; recruit adequately powered multicenter samples, including clinically hypogonadal populations where appropriate; extend intervention and follow-up durations; and give comprehensive safety endpoints, including prostate-specific antigen, liver function, renal function, adverse events, and reproductive endpoints, the same priority as hormone outcomes.
5. Conclusion
Oral fenugreek-derived preparations may be associated with a small increase in total testosterone in adult men, but the certainty of evidence is very low and no stable free-testosterone benefit was demonstrated. Symptom, sexual-function, body-composition, and performance outcomes may provide related contextual information, but they cannot substitute for the primary testosterone-axis evidence. Current evidence should be interpreted as surrogate biochemical evidence rather than proof of improved androgen bioavailability, fertility, or long-term safety, and it does not support strong clinical or commercial testosterone-boosting claims. Future randomized trials should prioritize prospective registration, chemically characterized formulation standardization, harmonized testosterone and SHBG/free-testosterone assays, clinically relevant populations, longer follow-up, and prespecified safety and reproductive endpoints.
